Exelixis Inc Stock (US30161Q1040): Quarterly earnings in focus after recent results

Exelixis shares remain in focus on Nasdaq after the oncology specialist reported its latest quarterly earnings, with revenue growth driven by flagship cancer drug Cabometyx and updated 2024 guidance.

Responsible: ad hoc news Earnings Desk. Reviewed prior to publication on June 15, 2026 at 4:09 PM ET. Details in the imprint.

Exelixis Inc remains on the radar of Nasdaq investors after the oncology-focused biotech recently reported its latest quarterly earnings, highlighting solid product revenue growth from Cabometyx and updates to its 2024 financial outlook.

Revenue growth and Cabometyx momentum define recent quarter

Exelixis Inc, a cancer-focused biotechnology company listed on Nasdaq under the ticker EXEL, recently posted its first-quarter 2024 financial results, showing continued top-line growth driven primarily by its flagship therapy Cabometyx (cabozantinib) for renal cell carcinoma and other tumor types.

According to the company’s earnings release, Exelixis generated total revenues of approximately $425 million for the quarter, up from around $407 million in the same period a year earlier, with the bulk coming from U.S. net product sales of Cabometyx. Management emphasized that demand in renal cell carcinoma and differentiated positioning in later-line settings contributed to stable prescription trends, while ongoing efforts in label expansion and combinations aim to support future growth.

The company also booked collaboration revenues related to its partnerships, including arrangements with Ipsen for ex-U.S. commercialization of cabozantinib and with other partners on pipeline programs. While product sales remain the dominant driver, Exelixis continues to benefit from milestone and royalty streams, which help diversify the revenue base versus a single-product biotech profile.

On the profitability side, Exelixis reported GAAP net income in the latest quarter, supported by its established commercial franchise, although earnings were tempered by continued investment in research and development. R&D spending reflects an expansive clinical program in solid tumors, including multiple Phase 3 and earlier-stage trials evaluating cabozantinib in combination with other agents as well as wholly owned and partnered pipeline candidates.

Exelixis also reiterated its focus on maintaining a strong balance sheet, highlighting a sizable cash, cash equivalents and investments position that provides flexibility for internal development and potential business development moves. The company has in recent years deployed capital into early-stage oncology assets and platform technologies designed to complement its small-molecule expertise.

Updated 2024 guidance underlines investment in pipeline and lifecycle management

Alongside its quarterly results, Exelixis provided an updated financial outlook for full-year 2024, signaling expectations for continued revenue growth while underscoring higher planned R&D spending to support its clinical pipeline and lifecycle-management strategy.

The company’s guidance framework calls for total revenues to increase versus 2023 levels, with U.S. Cabometyx net product sales expected to remain the primary contributor. Management noted that competitive dynamics in renal cell carcinoma and other tumor types remain intense, but Exelixis aims to defend and potentially expand its share through combination regimens, new indications and real-world data supporting clinical use.

On the expense side, Exelixis projects higher operating costs, particularly in R&D, as it progresses multiple programs targeting difficult-to-treat cancers. These include antibody-drug conjugates, next-generation targeted therapies and other modalities that seek to build on the scientific and commercial foundation laid by cabozantinib. The company has stressed that near-term margin pressure is a trade-off for attempting to establish a broader, more durable oncology portfolio.

In terms of capital allocation, Exelixis has in the past authorized share repurchase programs, reflecting management’s view of the company’s long-term prospects and balance-sheet strength. However, future buybacks remain discretionary and will depend on available opportunities in pipeline expansion, licensing or acquisitions that could enhance the company’s strategic positioning in oncology.

For now, Exelixis is positioning its 2024 outlook as a balance between maintaining profitability from its established Cabometyx franchise and investing aggressively to bring new therapies forward, with investors monitoring how the revenue trajectory and pipeline milestones line up against this guidance over the coming quarters.

Key facts on the Exelixis Inc stock

• Name: Exelixis Inc
• Industry: Biotechnology (oncology therapeutics)
• Headquarters: Alameda, California, United States
• Core markets: Oncology treatments, primarily in the United States and partnered ex-U.S. territories
• Revenue drivers: Cabometyx (cabozantinib) for renal cell carcinoma and other cancers, collaboration and royalty revenue from partners
• Listing: Nasdaq, ticker EXEL
• Trading currency: US dollar ($)

This article was created with a.i. assistance and editorially reviewed. Not investment advice, not a buy or sell recommendation. Trading in securities carries risks up to the total loss of capital.